Kalytera Therapeutics Inc (OTCMKTS:KALTF) has announced that it made a significant breakthrough with a cannabinoid-based developmental treatment for acute and chronic pain.
The announcement revealed that the cannabinoid compound treatment features a mechanism that targets alpha3 glycine receptor activation. The alpha3 glycine receptors block pin signals from reaching the brain when activated. Kalytera teamed up with Beetlebung Pharma Ltd on the treatment development program to determine which cannabinoid novel analogue would block pain signals through the alpha3 glycine receptor mechanism.
$KALTF & its research partner, Beetlebung Pharma Ltd., have carried out a medicinal chemistry program to identify a novel analogue of #CBD that will block #pain signals via the activation of the alpha3 glycine receptor channel in the spinal cord https://t.co/tCHdqhPq0c
— Kalytera Therapeutics (@kalyteraco) September 27, 2018
The cannabinoid-based acute and chronic pain treatment makes Kalytera Therapeutics the first company to introduce a solution that targets the alpha3 glycine receptors. It therefore marks a big win for the company. Kalytera Therapeutics managed to create a new compound by manipulating the Canabidiol structure.
The new compound is reportedly 40 times more potent than the alpha3 glycine receptor agonist, desoxy-CBD. Its potency is a key determinant for clinical testing to determine whether it is a good opioid substitute for treating chronic pain.
“The objective of our program is to develop a potent, non-psychotropic, oral analgesic for intractable pain that will be safe and well tolerated,” stated Kalytera CEO, Robert Farrell.
Farrell also added that the new compound can block pain without risks such as respiratory suppression as is the case with opioid analgesics and without addiction risks. He also stated that the company also managed to come up with a way to make the CBD compound water soluble. This is great news because treating patients in special cases such as surgical procedures or childbirth will become easier.
Such a major breakthrough also translates to good financial fortunes ahead for the company since the commercial opportunities are huge. A Transparency Market Research report claims that the global pain management market will be worth around $83 billion over the next five years. Patents for the CBD compound already exist in the U.S as well as other markets and Kalytera has already acquired an exclusive BLP global license for the compound. BLP is a cannabinoid-based therapeutics firm that is based in Israel.